Anti-platelet therapy in coronary heart disease

A new, produced in Russia, form of acetylsalicylic acid (ASA), Askolong, could substantially improve patients’ compliance to long-term anti-aggregant therapy. Oral Askolong (12,5 mg) is absorbed via oral mucosa and does not cause gastrointestinal adverse effects, which are the main reason for treatm...

Full description

Saved in:
Bibliographic Details
Main Authors: O. V. Ermakova, E. V. Kokurina, N. G. Kucheryavaya, E. V. Bochkareva
Format: Artigo
Language:Russo
Published: «SILICEA-POLIGRAF» LLC 2010-02-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
new forms of acetylsalicylic acid
anti-aggregant effect
adverse effects
askolong
Online Access:https://cardiovascular.elpub.ru/jour/article/view/2023
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items